Hutchmed Ltd on Friday said that its partner Takeda Pharmaceutical Co Ltd has been notified that the Committee for Medicinal Products for Human Use of the European Medicines Agency recommends.
Hutchmed notes CHMP s positive opinion for fruiquintinib approval lse.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lse.co.uk Daily Mail and Mail on Sunday newspapers.
Hutchmed Ltd on Tuesday jointly announced with Innovent Biologics that their new drug application for the combined fruquintinib and sintilimab treatment for endometrial cancer has been granted.
Hutchmed endometrial cancer treatment application accepted for review | Finance News shareprices.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from shareprices.com Daily Mail and Mail on Sunday newspapers.
Hutchmed Ltd on Thursday said its supplemental new drug application for savolitinib has been accepted for review by the China National Medical Products Administration.
If accepted, the Hong.